Sharp decline in 3Q Korean Orange Book listings, 45 companies, 79 cases
50% drop from the previous quarter…Hutecs Korea and DongKoo Bio & Pharma lead South Korea's new drug registrations
[Newsmp] The number of drugs registered in the Korean version of Orange Book by the Korean Ministry of Food and Drug Safety (MFDS) in the third quarter decreased significantly.
According to the MFDS information platform (https://nedrug.mfds.go.kr/), a total of 45 companies registered 79 cases in the Korean Orange Book in the last quarter. It was only half of the 131 cases in the same period last year, compared to 151 cases in the previous second quarter.
Hutecs Korea Pharmaceutical led with 6 registrations, followed by DongKoo Bio & Pharma with 5, and HK inno.N and Jeil Pharmaceutical with 4 each.
Following them, MEDICA KOREA, Celltrion, Daewon Pharmaceutical, Myungmoon Pharmaceutical, Samjin Pharmaceutical, and Jin Yang Pharmaceutical listed 3 drugs each, while MOTHER'S Pharmaceutical, Chong Kun Dang Pharmaceutical, Daewoo Pharm, Samik Pharmaceutical, SamChunDang Pharm, Hanmi Pharmaceutical, and Hyundai Pharmaceutical recorded 2 drugs each.
Other companies that registered one drug in the third quarter include Daewoong Pharmaceutical, BASKHANBIO Pharma, Binex, Boryung Pharmaceutical, Samoh Pharm, CMG Pharmaceutical, Ilhwa, GENUPHARMA, PharmGen Science, Korea PMG Pharm, Huons, Kyung Dong Pharmaceutical, Kwang Dong Pharmaceutical, Daewoong Bio, DAE HWA Pharmaceutical, DongKook Pharmaceutical, Samil Pharmaceutical, Shin Poong Pharmaceutical, Ahn-Gook Pharmaceutical, Korea Arlico Pharm, SK Chemicals, HLB Pharmaceutical, Unimed Pharm, JW Lifescience, Danagen, Genuone Sciences, Crystal Life Sciences, and Union Korea Pharm.